182 related articles for article (PubMed ID: 22009029)
1. Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.
Hofstetter G; Berger A; Schuster E; Wolf A; Hager G; Vergote I; Cadron I; Sehouli J; Braicu EI; Mahner S; Speiser P; Marth C; Zeimet AG; Ulmer H; Zeillinger R; Concin N
Br J Cancer; 2011 Nov; 105(10):1593-9. PubMed ID: 22009029
[TBL] [Abstract][Full Text] [Related]
2. The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancer.
Hofstetter G; Berger A; Berger R; Zorić A; Braicu EI; Reimer D; Fiegl H; Marth C; Zeimet AG; Ulmer H; Moll U; Zeillinger R; Concin N
Int J Gynecol Cancer; 2012 Mar; 22(3):372-9. PubMed ID: 22246403
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
4. The significance of p53 isoform expression in serous ovarian cancer.
Chambers SK; Martinez JD
Future Oncol; 2012 Jun; 8(6):683-6. PubMed ID: 22764765
[TBL] [Abstract][Full Text] [Related]
5. Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers.
Bischof K; Knappskog S; Hjelle SM; Stefansson I; Woie K; Salvesen HB; Gjertsen BT; Bjorge L
Sci Rep; 2019 Mar; 9(1):5244. PubMed ID: 30918304
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
7. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
8. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
9. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W
Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma].
Lin J; Du J; Zhang CY; Xie QT; Zhang B; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):655-60. PubMed ID: 21176529
[TBL] [Abstract][Full Text] [Related]
11. Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer.
Skirnisdottir I; Seidal T
Cancer Genomics Proteomics; 2013; 10(1):27-34. PubMed ID: 23382584
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of TAp73 and ΔNp73 protein expression in ovarian cancer: a series of 83 cases and review of the literature.
Hofstetter G; Berger A; Chamson M; Müller-Holzner E; Reimer D; Ulmer H; Uramoto H; Marth C; Zeimet AG; Zeillinger R; Concin N
Int J Gynecol Pathol; 2011 Nov; 30(6):527-31. PubMed ID: 21979586
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
16. The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer.
Bauerschlag DO; Schem C; Weigel MT; Von Kaisenberg C; Strauss A; Bauknecht T; Maass N; Meinhold-Heerlein I
J Cancer Res Clin Oncol; 2010 Jan; 136(1):79-88. PubMed ID: 19609560
[TBL] [Abstract][Full Text] [Related]
17. Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer.
Hofstetter G; Berger A; Fiegl H; Slade N; Zorić A; Holzer B; Schuster E; Mobus VJ; Reimer D; Daxenbichler G; Marth C; Zeimet AG; Concin N; Zeillinger R
Oncogene; 2010 Apr; 29(13):1997-2004. PubMed ID: 20101229
[TBL] [Abstract][Full Text] [Related]
18. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
[TBL] [Abstract][Full Text] [Related]
19. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
Vartiainen J; Lassus H; Lehtovirta P; Finne P; Alfthan H; Butzow R; Stenman UH
Int J Cancer; 2008 May; 122(9):2125-9. PubMed ID: 18098286
[TBL] [Abstract][Full Text] [Related]
20. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
